The foundation of InsuSense comes from the pioneering science of Anders Nykjaer. Professor Nykjaer has developed the field of Vps10p-domain receptors (Sortilins).
IST’s vision is to bring forward novel therapeutics, based on unique scientific understanding and intellectual property of the company, offering patients superior treatments.